Results 201 to 210 of about 40,773 (330)

A Serum Resistant Polymer with Exceptional Endosomal Escape and mRNA Delivery Efficacy for CRISPR Gene Therapy

Advanced Science, Volume 12, Issue 13, April 3, 2025.
A fluoropolymer, FD17, identified in a polymer library, exhibits exceptional serum stability and endosomal escape, enabling efficient mRNA delivery. FD17 facilitates the intracellular delivery of mRNAs encoding CRE, Cas9, and hyCBE for genome editing.
Jia Lv, Qianqian Fan, Yirou Zhang, Xujiao Zhou, Panting Yu, Xin Yu, Changchang Xin, Jiaxu Hong, Yiyun Cheng   +8 more
wiley   +1 more source

Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding

Journal of Lipid Research, 2013
Proprotein convertase subtilisin kexin-like 9 (PCSK9) promotes the degradation of low density lipoprotein receptor (LDLR) and plays an important role in regulating plasma LDL-cholesterol levels.
Hong-mei Gu, Ayinuer Adijiang, Matthew Mah, Da-wei Zhang   +3 more
doaj  

Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents [PDF]

, 2009
Alexis Baass, Geneviève Dubuc, Michel J. Tremblay, Edgard Delvin, Jennifer O’Loughlin, Émile Lévy, Jean Davignon, Marie Lambert   +7 more
openalex   +1 more source

Heart to heart with PCSK9

European Heart Journal, 2021
Kevin Chemello, Ali K Jaafar, Gilles Lambert   +2 more
openaire   +3 more sources

Contextualizing guidelines for the health system of Cyprus: Experiences and lessons learnt

Clinical and Public Health Guidelines, Volume 2, Issue 2, April 2025.
Abstract Background Cyprus is undergoing a major health reform with the recent establishment of the General Healthcare System (GHS). The GHS offers equal healthcare access through one primary insurer (Health Insurance Organization [HIO]) and benefits from a wide collaborative network of public and private healthcare providers.
Panayiotis Kouis, Hugh McGuire, Monika Kyriacou, Anneza Yiallourou, Anastasis Sioftanos, Ourania Kolokotroni, Haris Achilleos, Craig Grime, Pilar Pinilla‐Dominguez, Giorgos Giallouros, Christina Englezou, Contextualization group, George Athanasiou, Elias Avraam, Mary Avraamidou, Anastasios Bagourdis, Charis Charilaou, Stelios Christodoulou, Natasa Christofides, Theodoros Christophides, Vasilis Constantinidis, Dimitris Dimitriou, Stella Eleftheriadou, Christina Flourou, Savvas Frangos, Kyriakos Frantzeskou, Costas Hoplaros, Kyriakos Ioannou, Nikolaos Kadoglou, Chara Kalogirou, Vasileios Karathanos, Andreas Kostis, Andreas Kousios, Ekaterini Lambrinou, Emily Mavrokordatou, Michael Michael, Nicos Mitsides, Chrystalleni Mylonas, Georgia Orphanou, Elias Papasavvas, Doros Polydorou, Stavros Stavrou, Elena Theofanous, Despo Theodorou, Giannis Thrasyvoulou, Chryssa Tziakouri‐Shakalli, Theodora Vassiliou, Alexis Vrachimis, Panayiotis K. Yiallouros, Georgios K. Nikolopoulos   +49 more
wiley   +1 more source

Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization

Pharmacological Research
PCSK9 promotes the degradation of the low-density lipoprotein receptors and its inhibition by monoclonal antibodies or gene silencing approaches results in the reduction of plasma cholesterol levels coupled to that of cardiovascular events.
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, Ramona Stringhi, Laura D’Andrea, Filippo La Greca, Clara Cambria, Lina Vandermeulen, Elisa Zianni, Stefano Musardo, Silvia Roda, Fabrizia Bonacina, Sofia Nasini, Maria Giovanna Lupo, Nicola Ferri, Stefano Comai, Fabrizio Gardoni, Flavia Antonucci, Diego Scheggia, Monica Di Luca, Giuseppe Danilo Norata, Elena Marcello   +21 more
doaj  

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters [PDF]

, 2010
Bin Dong, Minhao Wu, Hai Li, Fredric B. Kraemer, Khosrow Adeli, Nabil G. Seidah, Sahng Wook Park, Jingwen Liu   +7 more
openalex   +1 more source

PCSK9 pipeline [PDF]

Nature Reviews Drug Discovery, 2016
openaire   +2 more sources

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease

Journal of Clinical Apheresis, Volume 40, Issue 2, April 2025.
ABSTRACT Elevated Lipoprotein(a) (Lp(a)) is a known independent cardiovascular risk factor. Lp(a) Lipoprotein Apheresis (LA) substantially reduces the number of cardiovascular events. The effect of LA treatment in hemodialysis (HD) patients remains unknown. Retrospective analysis of nine patients undergoing LA and HD.
Tilmann Röseler, Daniel Kayser, Georg Schlieper, Wanja M. Bernhardt   +3 more
wiley   +1 more source

The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. [PDF]

, 2013
Elguindy, A, Yacoub, MH
core   +1 more source